Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dostarlimab monotherapy in untreated stage II/III dMMR/MSI-H locally advanced rectal cancer
2022-003289-18Phase 2Active
- Sponsor
- GSK
- Start
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dostarlimab in rectal cancer, sponsored by GSK. Primary endpoint: cCR12 by ICR. Started Dec 2022; status: active.
02
Drugs
dostarlimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2022-003289-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003289-18.